Molecular Dynamics MegaBACE 1000 DNA sequencer sales ramp-up depends on initial market acceptance.
This article was originally published in The Gray Sheet
Executive Summary
MOLECULAR DYNAMICS MEGABACE 1000 DNA SEQUENCER FULL-SCALE LAUNCH is contingent on the level of market acceptance in the second phase of the company's three-stage roll-out strategy, the company says. "During the latter part of 1998, we will go into the broader market launch of this product, but that will depend on the level of demand we experience in" the ongoing phase-two marketing, President and CEO Jay Flatley told investors at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.